Journal of thoracic disease · 2026
Survival benefit of neoadjuvant therapies in patients with surgically resected non-small cell lung cancer with pathologic complete response.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Madeka Isheeta, Noueihed Khaled, Martin Jonathan, Koeneman Scott H, Woodroof Jacob, Rshaidat Hamza, Whitehorn Gregory L, Alaparthi Sneha, Grenda Tyler R, Evans Nathaniel R, Okusanya Olugbenga T
Аннотация
BACKGROUND: Although the prognostic value of pathologic complete response (pCR) status has varied based on neoadjuvant strategy for operable, advanced non-small cell lung cancer (NSCLC), its value after neoadjuvant chemoimmunotherapy as compared to the other strategies is unknown. We aim to investigate the long-term survival benefits in patients receiving neoadjuvant chemotherapy alone, chemoradiation, or chemoimmunotherapy for surgically resected NSCLC with pCR.
METHODS: A retrospective cohort review was completed utilizing the National Cancer Database from 2017-2020. Patients with cT1B-3A NSCLC who received neoadjuvant therapy prior to surgical resection, and pCR were included. Basic demographic information, short-term outcomes, and available surgical data were collected. Long-term outcomes were assessed via Kaplan-Meier analysis with log-rank tests and multivariable regression analysis.
RESULTS: We identified 584 patients between 2017 and 2020. A majority presented with clinical stage III NSCLC (64.4%, n=376) and underwent lobectomy (86.9%, n=505). A majority received chemoradiation (59.8%, n=349), followed by chemotherapy alone (25%, n=146) and chemoimmunotherapy (15.2%, n=89). There was a significant association with improved 5-year overall survival (OS) in patients who achieved PCR status between chemoimmunotherapy (84.4%) and chemoradiation (70%) (P<0.05). There was no significant difference in OS between neoadjuvant chemoimmunotherapy (84.4%) vs. chemotherapy alone (82%) (P=0.65).
CONCLUSIONS: In patients with NSCLC with pCR, there was a significantly greater association of OS in patients who received neoadjuvant chemoimmunotherapy compared to those who received chemoradiation. There was no significant survival difference between chemoimmunotherapy and chemotherapy alone.
METHODS: A retrospective cohort review was completed utilizing the National Cancer Database from 2017-2020. Patients with cT1B-3A NSCLC who received neoadjuvant therapy prior to surgical resection, and pCR were included. Basic demographic information, short-term outcomes, and available surgical data were collected. Long-term outcomes were assessed via Kaplan-Meier analysis with log-rank tests and multivariable regression analysis.
RESULTS: We identified 584 patients between 2017 and 2020. A majority presented with clinical stage III NSCLC (64.4%, n=376) and underwent lobectomy (86.9%, n=505). A majority received chemoradiation (59.8%, n=349), followed by chemotherapy alone (25%, n=146) and chemoimmunotherapy (15.2%, n=89). There was a significant association with improved 5-year overall survival (OS) in patients who achieved PCR status between chemoimmunotherapy (84.4%) and chemoradiation (70%) (P<0.05). There was no significant difference in OS between neoadjuvant chemoimmunotherapy (84.4%) vs. chemotherapy alone (82%) (P=0.65).
CONCLUSIONS: In patients with NSCLC with pCR, there was a significantly greater association of OS in patients who received neoadjuvant chemoimmunotherapy compared to those who received chemoradiation. There was no significant survival difference between chemoimmunotherapy and chemotherapy alone.